EXCESSNCT01189786
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
At risk: Primary completion moved at least 11 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 29 versions: 15 with changes below, 14 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Oct 2026 to Oct 2027
- Eligibility criteria expanded, about 19 words
- Site details revised at 1 of 2 sites
- Notable Primary completion date: Oct 2025 to Oct 2026
- Study completion date: Nov 2026 to Nov 2027
- Notable Eligibility criteria shortened, about 97 words
- Study description expanded, about 6 words
- Notable Enrollment target: 144 to 241
- Eligibility criteria expanded, about 197 words
- Primary endpoints revised (2)
- Study arms: 2 to 3
- Notable Primary endpoints: 1 to 2
- Secondary endpoints: 2 to 1
- Study description shortened, about 34 words
Show 9 earlier versionsHide 9 earlier versions
- Notable Eligibility criteria shortened, about 18 words
- Collaborators reordered
- Notable Primary completion date: Oct 2020 to Oct 2025
- Study completion date: Nov 2021 to Nov 2026
- Notable Primary endpoints: 2 to 1
- Secondary endpoints: 1 to 2
- Notable Enrollment target: 74 to 144
- Primary endpoints revised (2)
- Secondary endpoints expanded, about 5 words
- Minor Study sites revised (2)v11
- Notable Primary endpoints revised (2)v10
Notable Primary completion date: Oct 2015 to Oct 2020v9 Show 5 more changesShow less
- Eligibility criteria shortened, about 62 words
- Primary endpoints: 1 to 2
- Study completion date: Oct 2015 to Nov 2021
- Study description shortened, about 6 words
- Site contacts updated at 2 of 2 sites
- Notable Enrollment target: 20 to 74
- Eligibility criteria expanded, about 199 words
- Site contacts updated at 2 of 2 sites
- Study arms: 1 to 2
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study description revised
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
Cohort 2 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD34 Reagent system' as a "topoff" without the need for additional conditioning prior to the infusion. These patients who have already received SCT and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse.
Cohort 1 consists of patients receiving CD34+ selected peripheral blood stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The stem cells will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory.
Cohort 3 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD 34+ Reagent System' as a "topoff" with the need for additional conditioning prior to the infusion. These patients who have already received SCT with conditioning and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse.
Devices: CliniMACS CD34 Reagent system
Sites
2 sites in 1 country